AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oxford University's coronavirus vaccine project leader isn't as enthusiastic as you want him to be.

Oxford Professor Lowers Coronavirus Vaccine's Odds of Meeting September Deadline

NVIDIA

Lululemon Athletica

Lululemon Athletica, Nvidia, TJX Companies and AstraZeneca were our top stock trades for Friday. That said, let's look at the charts.

4 Top Stock Trades for Friday: NVDA, LULU, TJX, AZN

The United States has secured almost a third of the first one billion doses planned for AstraZeneca's experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their economies back to work.

U.S. secures 300 million doses of potential AstraZeneca COVID-19 vaccine

VanEck Vectors Biotech ETF

Loncar Cancer Immunotherapy ETF

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.

AstraZeneca Joins Coronavirus Vaccine Race, Great For Biotech ETFs

By pledging up to $1.2 billion in assistance, the Department of Health and Human Services has ensured its access to a large supply of the ChAdOx1 nCoV-19 vaccine -- assuming it works.

U.S. Seals Deal with AstraZeneca for 300 Million Doses of Potential Coronavirus Vaccine

AstraZeneca will receive up to $1.2 billion in Biomedical Advance Research and Development funding for its coronavirus vaccine, the U.K. drugmaker said Thursday — prompting AZN stock to pop.

Coronavirus Vaccine: How The U.S. Snagged A Third Of AstraZeneca's Doses

AstraZeneca's CEO says the US government's $1 billion investment in its coronavirus vaccine is a gamble -- but worth the risk.

AstraZeneca CEO says $1 billion vaccine bet is 'absolutely worth it'

AstraZeneca plc (NYSE: AZN), which is collaborating with the Oxford University to develop a vaccine for SARS-CoV-2, announced Thursday a funding commitment from the U.S.

AstraZeneca Receives Over $1B In BARDA Funding For Coronavirus Vaccine

The company says it has secured orders for 400 million doses of the as yet unproven vaccine, to be delivered from this September.

AstraZeneca Receives $1 Billion From U.S. Government To Produce Coronavirus Vaccine

The feds have ordered 300 million doses of a potential coronavirus vaccine from British drugmaker AstraZeneca, officials said Thursday. The company will get up to $1.2 billion from the US Department of Health and Human Services to speed the development and production of the vaccine with the goal of delivering the first doses as early.

US orders 300M doses of AstraZeneca’s coronavirus vaccine

Firm has capacity to make 1bn doses of Oxford University drug undergoing trials

AstraZeneca could supply potential coronavirus vaccine from September

AstraZeneca's Lynparza Label Expansion, And Other News: The Good, Bad And Ugly Of Biopharma

AstraZeneca has agreed to initially supply at least 400 million doses of Oxford University's coronavirus vaccine and secured total manufacturing capacity to produce 1 billion doses.

AstraZeneca receives $1 billion in US funding for Oxford University coronavirus vaccine

AstraZeneca (LON: AZN) is collaborating with the University of Oxford to develop its COVID-19 vaccine.  In a statement on Thursday, the company said that results of its clinical trial (early stage) are expected presently.

AstraZeneca signs first agreements to deliver at least 400 million doses of COVID-19 vaccine

Merck

FDA approves AstraZeneca (AZN)/Merck's (MRK) PARP inhibitor Lynparza for HRR gene-mutated metastatic castration-resistant prostate cancer. The approval was based on data from the phase III PROfound study.

AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer

AstraZeneca has said it has the capacity to manufacture one billion doses of the University of Oxford's potential COVID-19 vaccine and plans to begin supplying it in September.

AstraZeneca could begin supply of potential COVID-19 vaccine in September

AstraZeneca AZN, +0.39% AZN, +2.37% said it's taking steps to make the University of Oxford's COVID-19 vaccine widely accessible around the world.

AstraZeneca says it can produce 1 billion doses of Oxford's potential COVID-19 vaccine

Lynparza could generate blockbuster sales as a new treatment option that isn't hormone-based.

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

Shares of AstraZeneca AZN, +0.22% gained 0.7% and Merck & Co. Inc.'s stock MRK, -2.72% was up 0.7% in premarket trading on Wednesday after the companies said the Food and Drug Administration had approved their cancer drug Lynparza for certain patients with prostate cancer.

AstraZeneca and Merck's Lynparza gets FDA approval for prostate cancer

British pharmaceutical company, AstraZeneca (LON: AZN) collaborated with the U.S-based Merck & Co. (NYSE: MRK) on Lynparza drug as a treatment option for prostate cancer.

U.S. FDA approves AstraZeneca and Merck’s Lynparza as a treatment for prostate cancer

The FDA assigns a Breakthrough Therapy status to AstraZeneca's (AZN) Enhertu for treating patients with metastatic NSCLC whose tumors have a HER2 mutation.

AstraZeneca's Enhertu Gets Breakthrough Therapy Tag for NSCLC

Moderna

Pfizer

With about eight coronavirus vaccine candidates in clinical trials and 110 more in clinical testing, the race to a commercial product is intensifying.

These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

AstraZeneca's Cure For Your Ailing Dividend Portfolio: Sustainable Growth

Bristol-Myers

Eli Lilly

Sanofi

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.

Drug Sector Highly Resilient Amid Coronavirus Mayhem: 5 Picks

FDA approves AstraZeneca's (AZN) PARP inhibitor Lynparza as a first-line maintenance treatment for HRD-positive advanced ovarian cancer. The approval was based on data from the phase III PAOLA-1 study.

News for AstraZeneca Stock (AZN)